Oxford American handbook of oncology. Second Edition. Oxford University Press (2015)
When intracellular proteins are labeled by the addition of the ubiquitin protein, they are marked for degradation into smaller peptides by the intracellular proteasome complex.
- Mechanism: binds and reversibly inhibits the 26S proteasome and inhibits nuclear factor (NF)-1B
- Route: intravenous
- Uses: multiple myeloma, mantle cell lymphoma, other non-Hodgkin’s lymphomas
- Notes: can cause sensory neuropathy. Pulmonary complications including adult respiratory distress syndrome have been reported.